105 related articles for article (PubMed ID: 2192772)
21. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
Gagnon C; Gomez-Mancilla B; Bédard PJ; Di Paolo T
Neurosci Lett; 1993 Nov; 163(1):31-5. PubMed ID: 7905197
[TBL] [Abstract][Full Text] [Related]
22. [3H]SCH 23390 binding to D1 dopamine receptors in the basal ganglia of the cat and primate: delineation of striosomal compartments and pallidal and nigral subdivisions.
Besson MJ; Graybiel AM; Nastuk MA
Neuroscience; 1988 Jul; 26(1):101-19. PubMed ID: 2901690
[TBL] [Abstract][Full Text] [Related]
23. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.
Gagnon C; Gomez-Mancilla B; Markstein R; Bédard PJ; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):667-76. PubMed ID: 8588064
[TBL] [Abstract][Full Text] [Related]
24. Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson's disease.
Pifl C; Nanoff C; Schingnitz G; Schütz W; Hornykiewicz O
J Neurochem; 1992 Jun; 58(6):1997-2004. PubMed ID: 1349341
[TBL] [Abstract][Full Text] [Related]
25. Dopamine D1 and D2 receptors visualized in MPTP treated C57 mice by in vitro autoradiography: lack of evidence of receptor modifications in parkinsonian mice.
Camps M; Ambrosio S; Ballarin M; Reiriz J; Blesa R; Mahy N
Pharmacol Toxicol; 1989 Sep; 65(3):169-74. PubMed ID: 2682595
[TBL] [Abstract][Full Text] [Related]
26. D1 and D2 dopamine receptors in caudate-putamen of nonhuman primates (Macaca fascicularis).
Madras BK; Fahey MA; Canfield DR; Spealman RD
J Neurochem; 1988 Sep; 51(3):934-43. PubMed ID: 2970527
[TBL] [Abstract][Full Text] [Related]
27. Autoradiographic distribution of non-dopaminergic binding sites labeled by [3H]haloperidol in rat brain.
Contreras PC; Quirion R; Gehlert DR; Contreras ML; O'Donohue TL
Neurosci Lett; 1987 Mar; 75(2):133-40. PubMed ID: 3033560
[TBL] [Abstract][Full Text] [Related]
28. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
Pope-Coleman A; Tinker JP; Schneider JS
Synapse; 2000 May; 36(2):120-8. PubMed ID: 10767059
[TBL] [Abstract][Full Text] [Related]
29. Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Rouillard C; Bédard PJ; Di Paolo T
Eur J Pharmacol; 1990 Aug; 185(2-3):209-15. PubMed ID: 2253695
[TBL] [Abstract][Full Text] [Related]
30. Perinatal asphyxia induces long-term changes in dopamine D1, D2, and D3 receptor binding in the rat brain.
Chen Y; Hillefors-Berglund M; Herrera-Marschitz M; Bjelke B; Gross J; Andersson K; von Euler G
Exp Neurol; 1997 Jul; 146(1):74-80. PubMed ID: 9225740
[TBL] [Abstract][Full Text] [Related]
31. Up-regulation of dopamine receptors in the brain of the spontaneously hypertensive rat: an autoradiographic analysis.
Kirouac GJ; Ganguly PK
Neuroscience; 1993 Jan; 52(1):135-41. PubMed ID: 8433803
[TBL] [Abstract][Full Text] [Related]
32. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
[TBL] [Abstract][Full Text] [Related]
33. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
34. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology.
Imai H; Nakamura T; Endo K; Narabayashi H
Brain Res; 1988 Dec; 474(2):327-32. PubMed ID: 3264746
[TBL] [Abstract][Full Text] [Related]
35. Subthalamotomy-induced changes in dopamine receptors in parkinsonian monkeys.
Jourdain VA; Morin N; Morissette M; Grégoire L; Di Paolo T
Exp Neurol; 2014 Nov; 261():816-25. PubMed ID: 25172808
[TBL] [Abstract][Full Text] [Related]
36. Methamphetamine-induced reduction in D1 and D2 dopamine receptors as evidenced by autoradiography: comparison with tyrosine hydroxylase activity.
McCabe RT; Hanson GR; Dawson TM; Wamsley JK; Gibb JW
Neuroscience; 1987 Oct; 23(1):253-61. PubMed ID: 2891082
[TBL] [Abstract][Full Text] [Related]
37. Localization and function of dopamine receptors in the subthalamic nucleus of normal and parkinsonian monkeys.
Galvan A; Hu X; Rommelfanger KS; Pare JF; Khan ZU; Smith Y; Wichmann T
J Neurophysiol; 2014 Jul; 112(2):467-79. PubMed ID: 24760789
[TBL] [Abstract][Full Text] [Related]
38. Comparison of dopamine binding sites in the rat superior cervical ganglion and caudate nucleus.
Ariano MA
Brain Res; 1987 Sep; 421(1-2):245-54. PubMed ID: 2961410
[TBL] [Abstract][Full Text] [Related]
39. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
[TBL] [Abstract][Full Text] [Related]
40. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
Kuno S
Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
